Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Walking away from stroke: simple step goals may stabilize artery plaque

NCT ID NCT04053166

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether a 6-month home-based walking program could reduce dangerous bleeding inside carotid artery plaque in people with significant blockages but no stroke symptoms. Fifty-six participants either followed an individualized step goal (with coaching) or received usual care. The researchers used MRI to measure plaque vulnerability before and after the program.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
individualized home-based physical activity (walking program with step goals and coaching)
What this could lead to
If it works, this could show that a simple walking program helps stabilize carotid plaque, potentially reducing stroke risk without surgery.
What could go wrong
This is a small, early study with only 56 participants, so results may not apply widely. The intervention is modest (increasing steps), and the main outcome is an MRI marker, not actual stroke reduction.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

56 people

The number who actually took part.

Started

Dec 2019

Finished

Sep 2022

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient with an carotid atheromatous plaque with ≥ 50% North American Symptomatic Carotid Endarterectomy Trial (NASCET) stenosis * Patient from vascular surgery department of the Louis Pradel Hospital of the Hospices Civils de Lyon, but not operated * Males and females aged over 18 years old * No contra-indication to physical activity with index performance (PS) \< 2 * Available and voluntary to invest in the study throughout its duration (6 months) * Able to understand, read and write French; * a social security system or similar; * Having dated and signed informed consent. Exclusion Criteria: * Transient ischemic attack (TIA) or ipsilateral cerebral infarction less than 6 months * History of ipsilateral carotid surgery or cervical irradiation; * Cancer, heart failure, seropositivity; * Coronary risk; * Renal failure (Cockcroft clearance of creatinine \< 30 milliliter/minute (mL/min); * Contraindication and precautions for use related to Prohance: hypersensitivity to the active substance or to any of the constituents of Prohance, renal insufficiency with clearance \<30 ml / min / 1.73 m², probability of convulsions during the higher examination in patients with epilepsy or brain injury, pregnancy, breastfeeding; * Contraindication to MRI: ferromagnetic material (including pacemaker, implantable defibrillators, cardiac valve prostheses, cochlear implants, neurostimulators, implanted automated injection equipment, intraocular metallic foreign bodies, neurosurgical and vascular clips); * Carotid occlusion; * ipsilateral intracranial stenosis; * Risk of pregnancy or proven pregnancy on interrogation data. Breastfeeding; * Patient under guardianship, under curatorship or safeguard of justice; * inability to express consent; * uncontrolled cardiological or neurological diseases; * Impossibility of being followed for medical, social, geographical or psychological reasons throughout the duration of the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Carotid atherosclerosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Hôpital Louis Pradel

    Bron, 69500, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.